The recent development of effective immune checkpoint inhibition (ICI), first demonstrated in melanoma, has revolutionized cancer treatment. Monoclonal antibodies blocking the immune checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1) have shown substantial clinical benefit in a subset of patients across tumor types and in both the metastatic and adjuvant settings. In this article, we review the interaction between the immune system and solid tumors, and describe modes of immune response failure and the physiologic role of immune checkpoints. We also review the known mechanisms of immune checkpoint inhibitors, focusing on US FDA-approved agents targeting CTLA-4 and PD-1. Within this framework, we classify hypothesized tumor intrinsic and extrinsic predictive markers for response and resistance to ICI, and map them to their putative underlying biological mechanism. Finally, we outline future directions in ICI, including the development of new therapeutic targets, rational combination therapies, integrated predictive models for individual patients to optimize therapy, and expansion into different disease types.
Clinically evident solid tumors must be considered to have already successfully evaded this immune response. Such evasion occurs through dysfunction of one or more aspects of the tumor-immunity cycle, and markers of response and resistance and their underlying mechanisms can be mapped to their effect within this cycle.
The development of immune checkpoint inhibition, particularly targeting cytotoxic T lymphocyte-associated antigen 4 and programmed death 1 receptor, has revolutionized cancer care, with durable responses in a subset of patients across different cancer types.
Mechanisms of resistance to these agents are being recognized, and novel therapeutic targets and combinations are being tested to induce immune response and overcome resistance mechanisms.
Introduction
Treatment of metastatic cutaneous melanoma has undergone a dramatic transformation over the past decade with the advent of molecular targeted therapies targeting BRAF/ MAPK signaling, and immune checkpoint inhibition (ICI) therapy targeting programmed death-1 (PD-1), its ligand PD-L1, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). For the approximately 40% of melanoma patients whose tumors harbor oncogenic mutations in BRAF [1, 2] , molecular-targeted therapy targeting BRAF/ MAPK signaling is effective (response rate [RR] > 80%), but the response is often short-lived (median progressionfree survival [PFS] approximately 9-11 months) owing to the development of resistance [3] . Numerous mechanisms of acquired resistance to BRAF/MAPK inhibition have been reported, and translational efforts from bedside to bench led to preclinical findings [4, 5] that have served to inform the next generation of clinical trials targeting resistance to BRAF/MAPK therapy (e.g. trials of downstream ERK inhibitors [6, 7] (see the review by Arozarena and Wellbrock [8] ). Single-agent or dual immune checkpoint blockade (ICB) has shown dramatic clinical activity in patients with advanced melanoma, demonstrating longlasting, durable responses in a subset of patients. Unfortunately, innate resistance is seen in 40-50% of patients, and robust clinicopathologic features to guide the use of ICB are lacking. Unlike BRAF/MAPK-targeted therapy, mechanisms of both innate and acquired resistance are incompletely characterized, although emerging studies have identified novel mechanisms of acquired resistance to anti-PD-1/PD-L1 or anti-CTLA-4 therapy.
ICI therapy has shown clinical activity across several cancer types, including melanoma, for which approved treatments now include anti-PD-1 (nivolumab, pembrolizumab), anti-CTLA-4 (ipilimumab), and combination anti-PD-1/CTLA-4 regimens (nivolumab-ipilimumab). Twentytwo percent of melanoma patients treated with ipilimumab showed evidence of continued durable disease control or response 5-10 years after starting therapy [9] . Single-agent PD-1 blockade in the first-line is effective in 40-45% of patients with advanced melanoma [10] [11] [12] . Combination immunotherapy or dual ICB (anti-PD-1 + anti-CTLA-4) shows response in patients with metastatic melanoma (RR 58%) compared with single-agent anti-PD-1 (RR 43.7%) or anti-CTLA-4 (RR 19%); however, over half of the patients experienced significant (grade III/IV) toxicity from the combined treatment regimen [13, 14] versus one-quarter of patients treated with anti-CTLA-4 or anti-PD-1 single-agent therapies [12] . Despite improved RRs with dual ICI therapy, overall survival has not yet been proven to be better than single-agent PD-1 blockade [12] .
In this review, we focus on the emerging mechanisms of acquired resistance to ICB therapy, building off the expanding paradigm of acquired resistance to molecular-targeted therapies, and discuss strategies to overcome ICB resistance. To provide the appropriate clinical context for the discussion of mechanism of acquired resistance to ICB, we first review the model of intrinsic immune response to cancer, describe modes of immune response failure, illustrate roles of immune checkpoint molecules and the mechanisms of CTLA-4 and PD-1 checkpoint blockade, review markers and mechanisms of resistance to ICB, and outline future directions, and the expanding array of 'rational' combination therapies meant to overcome resistance to ICB.
Tumor-Immune Interactions
The immune system has a complex set of checks and balances to allow flexible and adaptive responses to a variety of pathogens while avoiding autoimmunity. The immune system is regulated to avoid activation with self-antigens through early thymic editing of T and B cells with strong binding affinities to self-antigens. However, tumor cells have mutations leading to neoantigen formation that can be recognized as 'foreign' and activate the immune response. Evidence indicates that there is significant immune suppression of malignant and pre-malignant cells and, indeed, clinically detected malignant tumors can be thought of as having evaded the immune response [15, 16] .
Physiologic Immune Response to Tumor
In a functioning immune response, antigen-presentation cells (APCs; primarily dendritic cells [DCs] ) scavenge the detritus of dead tumor cells in the tumor microenvironment, which includes neoantigens (Fig. 1a) . Dying tumor cells release damage-associated molecular patterns (DAMPs, including nucleic acids, uric acid, ATP, heatshock proteins, mitochondrial-derived molecules), which are detected by APCs, thereby inducing type I interferon (IFN) secretion [17] , leading to activation and maturation of DCs. These activated DCs travel to lymph nodes, where they prime T cells with T-cell receptors (TCRs) that bind to cross-presented MHC-I neoantigen and MHC-II neoantigen complexes, along with a co-stimulatory signal primarily through B7-CD28 binding (Fig. 1b) in addition to other costimulatory molecule interactions, including OX40:OX40L, 4-1BBL:4-1BB, CD70-CD70L, and GITRL:GITR [18] . These primed T-cells then proliferate and traffic back to the tumor site following a cytokine signal (e.g. CXC chemokine ligand [CXCL]9 and CXCL10 binding to CXCR3 on the T cells), where, upon binding to their matching MHC-I neoantigen cognate, they secrete IFN-γ (Fig. 1c) , leading to a 'feed-forward' cycle with immunostimulatory effects on macrophages, monocytes, and natural killer (NK) cells, and increased expression of MHC-I and II antigen-presentation complexes by tumor cells and APCs. Recognition of MHC-I neoantigen complexes leads to cytotoxic responses by effector T cells and tumor cell killing. In addition to the positive-feedback cycle of immunostimulatory effects of IFN-γ, a negative regulatory cycle is also initiated, with upregulation of immune checkpoints (most notably PD-L1) in response to IFN-γ, which bind to their cognate receptors (e.g. PD-1) expressed on the surface of cytotoxic T cells, diminishing their proliferation and effector function. This concurrent upregulation of negative regulators protects normal cells and, in the physiologic setting, serves to wind down the immune response after clearance of the pathogen or malignancy.
Failure of Immune Response to Tumor
Any failure of the steps leading to cytotoxic effector response to the tumor may lead to immune evasion, and clinically detected solid tumors must be considered to have successfully evaded the immune response. Broadly, three phenotypes [19] are seen that suggest failure at different points in the immune response: . This suggests that the immune response has been successful up to and including recruitment of a lymphocytic infiltrate into the tumor, but has failed to clear the tumor. As has been best-characterized in models of chronic viral infection [24] , chronic antigen stimulation without clearance leads to a T-cell 'exhaustion' phenotype with increased expression of immune checkpoint molecules (most prominently PD-1, but including TIGIT, LAG-3, TIM3) and reduced proliferation and cytotoxic effector function [25] . Strong engagement of the PD-1 negative regulatory signaling pathway is a well-characterized mechanism of immunoevasion, with one marker being high levels of PD-L1 expression by tumors. Indeed, response to blockade of the PD-L1/ PD-1 axis is associated with high PD-L1 expression in non-small cell lung cancer (NSCLC) in multiple settings [26, 27] , and classical Hodgkin's lymphoma, where a defining feature is amplification of the genomic locus, including PD-L1/PD-L2 [28] , has a 60-70% RR to PD-1 blockade. However, tumors without high PD-L1 expression still have response to PD-1 blockade [27] , suggesting that other mechanisms of immune evasion may be at work. 3. Excluded immune response (example: colorectal cancer, pancreatic cancer). While immune cells may be seen within the tumor microenvironment, they are segregated from infiltrating the tumor itself via stromal and tumor cell secretion of extracellular matrix proteins [29] . This suggests that priming and recruitment of lymphocytes has occurred, but immune evasion occurs, in part, through physical exclusion of immune cells from the tumor microenvironment or through secreted inhibitory factors.
Mechanisms of Action and Clinical Activity of Immune Checkpoint Inhibitors
Both positive and negative checkpoint signaling are found throughout the immune response and are obvious therapeutic targets. Ipilimumab, the first US FDA-approved checkpoint inhibitor, is a monoclonal antibody that targets CTLA-4, an inhibitory checkpoint receptor that is transiently expressed on naive T cells when the TCR is engaged during T-cell priming. CTLA-4 binds to B7 on APCs, competitively disrupting the B7-CD28 'second-signal', which is needed for T-cell activation and proliferation, thus serving as a negative regulator of T-cell priming [30] . Thus, one mechanism of CTLA-4 inhibitors is to increase T-cell priming and generate an increased diversity of T-cell response to tumor neoantigens [31] . Preclinical studies also demonstrate that ipilimumab, an immunoglobulin (Ig)G1 monoclonal antibody, has a direct effect depleting Tregs, which constitutively express CTLA-4 at high levels through antibody-directed, cell-mediated cytotoxicity (ADCC) [32, 33] . Thus, depletion of Tregs, which negatively regulate effector T cells, is another mechanism of the anti-tumor effect of ipilimumab [34, 35] . Finally, initial data from ipilimumab-treated human and murine tumors by Allison and colleagues suggest that CTLA-4 blockade results in expansion of a subset of CD4 + helper T cells [35] , which may be part of its mechanism of action. PD-1 is upregulated in effector T cells upon TCR engagement, and when engaged with its ligands PD-L1 and PD-L2 is a negative regulator of T-cell proliferation and cytotoxic function. As discussed previously, PD-1 is part of the negative regulatory cycle, which protects normal cells and ends the immune response after clearance of pathogen or malignancy in the physiologic setting. However, on sustained TCR-antigen engagement without clearance, as occurs in chronic viral infection or malignancy [36] , epigenetic changes occur in effector T cells and they develop an 'exhausted' phenotype with decreased proliferation and cytotoxic function, and higher expression of PD-1 and other inhibitory checkpoint molecules (including TIGIT, TIM-3, etc.) [37] . Anti-PD-1 and PD-L1 antibodies target this signaling axis and have been demonstrated in clinical and preclinical studies to restore the cytotoxic and proliferation activity of 'exhausted' T cells [35, 36] , although the epigenetic changes underlying the exhausted phenotype are not reverted [38] . Thus, PD-1/PD-L1 inhibition is thought to work through reactivation of effector T cells in the tumor microenvironment and is consistent with the clinical observation that tumors with 'exhausted immune response' (i.e. with ineffective tumor-infiltrating lymphocytes) as a class (e.g. melanomas, RCCs, lung cancers) and as individual tumors are most responsive to anti-PD-1 therapy. However, tumors without obvious immune infiltrate can also respond to anti-PD-1 therapy, and additional mechanisms of the PD-1/PD-L1 blockade are being developed.
Markers and Mechanisms of Response and Resistance to Immune Checkpoint Inhibition (ICI)

Response to ICI
Although predictors of response and resistance to PD-1/ PD-L1 and/or CTLA-4 blockade have remained elusive, PD-L1 expression, deficiency of mismatch DNA repair pathway (MMRd), and tumor mutational/neoantigen load have been the most commonly described markers of response (Table 1) . High PD-L1 expression has been associated with response to PD-1/PD-L1 expression in NSCLC [27] , consistent with PD-L1/PD-1 signaling as the tumor mechanism of immune evasion, and is part of the FDA-approved indication in certain clinical settings (e.g. PD-L1 expression > 50% in first-line therapy of metastatic NSCLC for pembrolizumab). However, in other settings, the lack of PD-L1 expression does not rule out response to PD-1 blockade (e.g. melanoma, RCC), suggesting alternative mechanisms of PD-1 blockade, and thus is not part of the FDA-approved indication for these diseases. Tumors with deficiency of the MMRd, as occurs congenitally in Lynch syndrome (commonly caused by a defective copy of a mismatch DNA repair gene, associated with a high risk of hereditary nonpolyposis colorectal cancer, endometrial cancer, and other cancers) have a mutation load 10-100 times that of other cancers of the same type without MMRd, and were demonstrated to have a > 50% RR to PD-1 blockade [39] across tumor types. This led to the ground-breaking FDA approval for pembrolizumab based solely on MMRd status independent of tumor type.
The mechanism of response to immunotherapy in MMRd tumors is thought to be due to their higher mutation (and thereby neoantigen) burdens, leading to a higher likelihood of immune response. Consistent with this mechanism, tumor types with higher mutational burden have higher RRs to immunotherapy [40] , and higher mutation loads have been found in responders versus non-responders within the same tumor types [41] [42] [43] [44] . Mutations in POLE, a polymerase involved in DNA replication, leads to even higher mutational loads in tumors, and have been associated with response to immunotherapy [45, 46] . Recent work suggests that small insertion or deletion mutations (indels) lead to higher numbers of strongly binding neoantigens compared with single nucleotide variants, and this may partially explain the response of RCC, a tumor type with low mutational loads but a higher proportion of indels, to immunotherapy [47] . However, no threshold of mutational load specifically or sensitively distinguishes responders and non-responders, and, as an individual biomarker, it is a poor predictor of response.
The mechanism underlying the observation of higher PD-L1 expression in responders is the presence of an existing immune response. As previously discussed, PD-L1 expression is part of the physiologic downregulation of the immune response induced in response to IFN-γ signaling. High levels of PD-L1 expression by tumor cells suggests the co-option of this regulatory mechanism for immune evasion by the tumor, and, in essence, is a 'break glass in case of emergency' adaptation that leaves these cells particularly vulnerable to PD-1/PD-L1 blockade. Thus, restoration of effector T-cell function with a PD-1/PD-L1 inhibitor leads to tumor cell killing and disease response. The presence of an immune infiltrate within responding tumors corresponding to an existing but ineffective immune response has been described since the earliest studies of patients treated with ICB [19, 48] , and is reflected in the discovery of a cytolytic signature as a marker of immunotherapy response in the transcriptome of tumor samples [49] . More recently, increased immune infiltrate in on-therapy tumor samples [56] [57] [58] has been associated with response to therapy [48, 50] . However, as in mutation load, the use of these markers to predict response to immunotherapy is challenging; results differ by tumor type, therapeutic agent, and assay used [51] (e.g. specific PD-L1 antibodies used to determine PD-L1 expression), and well-designed clinical trials are needed to determine clinically appropriate thresholds. Alterations in tumor-specific pathways constitute a third mechanism underpinning described markers of response to immunotherapy. For example, loss of function alterations in PBRM1, a component of the pBAF complex that is part of the epigenetic machinery, have been associated with response to immunotherapy in RCC [52] . Concurrently, loss of components of the pBAF complex, including PBRM1, were independently discovered as conferring sensitivity to effector T-cell cytotoxicity in an unbiased CRISPR screen [53] . In the setting of von Hippel-Lindau (VHL) loss as an oncogenic driver (e.g. the vast majority of clear-cell RCC), PBRM1 acts as a tumor suppressor, and its loss results in tumorigenesis through amplification of hypoxia-driven pathways [54] and rescue of VHL-loss-associated replicative stress [55] , but also inhibits the tumor cell's ability to downregulate response to apoptotic signals [53] from cytotoxic T cells (e.g. through FAS/FASL signaling). Other described markers of response to immunotherapy include downregulation of transforming growth factor (TGF)-β1 signaling [56, 57] and vascular endothelial growth factor A (VEGFA) secretion [58] .
Resistance to ICI
Acquired resistance to cancer therapies can be divided into processes that occur via population-level changes, as well as changes at a single cancer cell level [59] . Acquired resistance at the population level involves a selection of inherently 'fit' subpopulations of cells that expand in response to specific anticancer therapy, while less-fit cells are effectively killed in response to therapy. This population of cells existed in the initial population prior to therapy, but possessed the appropriate characteristics to survive treatment. Furthermore, in response to the selective pressure imposed by cancer therapy, this population of cells survived, grew, and replaced the initial population. Single-cell adaptation, also called 'homeostatic resistance', involves engaging intracellular signaling cascades and transcriptional changes in response to anticancer therapy.
Multiple tumor intrinsic and extrinsic markers have been proposed to predict resistance to ICI ( Table 2) . One of the best-validated and characterized mechanisms is the downregulation of antigen-presentation machinery. Deletions and deleterious alterations in B2M and human leukocyte antigen (HLA) alleles, components of the MHC-I molecule required for antigen presentation, have been demonstrated to be associated with a gene expression signature of cytotoxic immune cells in an analysis of 4512 tumors across 11 tumor types [49] , consistent with downregulation of antigen presentation by the tumor to evade a cytotoxic T-cell antigenspecific immune response. An acquired deleterious mutation in B2M was found in a late-progressing lesion from a melanoma patient with initial response to PD-1 blockade [60] . In a larger longitudinal cohort of 17 melanoma patients treated with ICI with subsequent progression, loss of or deleterious mutations in B2M mutation were found in progressive lesions in three patients with initial response to therapy and two patients with intrinsic resistance [61] . In a study of 14 ICI-resistant lung cancer patients, B2M loss and concomitant loss of expression of MHC-I expression was found in a resistant patient, and downregulation of B2M in patientderived xenografts was found in two other patients [62] . Subsequent functional validation demonstrated that B2M knockout conferred resistance to PD-1 blockade in vivo in an immunocompetent mouse lung cancer model [62] . Loss of HLA genes is found in 40% of NSCLCs, resulting in a loss of MHC-I peptide presentation, and is associated with resistance to immunotherapy in NSCLC [63] . Interestingly, mutations in JAK1 and JAK2, key intermediate components of IFN signaling pathways, have been described as associated with both innate [64] and acquired resistance [60] , and may function through inactivation of the tumor intrinsic response to IFN-γ, including upregulation of antigen presentation. Alternatively, since PD-L1 is upregulated through IFN signaling, deleterious alterations in JAK1/JAK2 may indicate that the tumor has developed alternate immuneevasive mechanisms other than PD-L1 upregulation, and thus blockade of the PD-L1/PD-1 axis is unlikely to lead to effective reactivation of the immune response. More generally, loss of heterozygosity (LOH) in a long list of genes associated with IFN-γ pathway activity has been statistically associated with resistance to ICB in a small cohort of 16 melanoma patients treated with anti-CTLA-4 therapy, and retrospectively validated in a larger independent cohort of melanoma patients [65] , although the causality and functional association between this aggregate biomarker and resistance is unclear.
Other tumor intrinsic mechanisms have been described to confer resistance to immunotherapy. In an exceptional responder to PD-1 checkpoint blockade with metastatic leiomyosarcoma, the one remaining resistant metastatic lesion after therapy was found to have acquired a PTEN homozygous deletion compared with pretreatment responsive lesions [66] . The absence of PTEN protein expression in pre-PD-1 inhibitor treatment tumors from metastatic melanoma patients was associated with resistance and tumor growth on PD-1 inhibitor treatment, and preclinical studies suggest that upregulation of immunosuppressive cytokines, including VEGF, may be part of the mechanism [67] , leading to reduced T-cell infiltration and an increase in suppressive immune cells, including myeloid-derived suppressor cells (MDSCs) and Tregs [68] . Recent work by Xiao and colleagues [69] demonstrated the association of PTEN deletion with increased expression of DKK2 in human tumors. Administration of DKK2 in a mouse model inhibited the PD-1 blockade-induced effects of increased CD8 tumor-infiltrating lymphocytes and activation of NK and CD8 T cells [69] . Of note, PTEN mutations/deletions are seen in approximately 20% of cutaneous melanomas [70] .
Upregulation of the WNT-β-catenin signaling pathway in tumor cells has been associated with decreased recruitment of tumor-infiltrating T cells in melanoma tumor samples [20] through downregulation of CCL4, a dendritic-cell recruitment cytokine, leading to subsequent failure of T-cell priming and activation and lack of an immune response.
In a retrospective analysis of melanoma patients treated with CTLA-4i, cancer cell aneuploidy (e.g. copy number gains or losses in the cancer genome) has been associated with lower levels of a cytotoxic cell signature, and described as a biomarker of poorer response to immunotherapy [71] . In a cohort of 53 metastatic melanoma patients sequentially treated with CTLA-4 blockade, then PD-1 blockade on progression [72] , aneuploidy was found to be higher in nonresponders to CTLA-4 inhibition, with recurrent copy loss in tumor suppressor genes, including PTEN, suggesting a mechanism of resistance.
Upregulation of alternative negative immune checkpoint molecules has been suggested as an alternate mechanism of ICB resistance, with upregulation of VISTA on CD4, CD8, and M2-subtype macrophages in patients treated with CTLA-4 blockade [73] . In a study of genetically engineered mouse models of lung cancer treated with PD-1 blockade, TIM-3 (an inhibitory immune checkpoint) was upregulated in tumor-infiltrating CD4 and CD8 T cells after progression on anti-PD-1 therapy [74] .
Transformation of epithelial-origin tumors to mesenchymal, stem-like cells is well-known as a mechanism of malignant transformation and metastatic progression [75] . A gene expression signature associated with this transformation has been associated with innate resistance to PD-1 blockade in a cohort of 38 metastatic melanoma patients [76] .
It is worth noting that amplification of MDM2/4, which suppress the master tumor suppressor and regulator TP53, has been associated with a 'hyper-progressor' phenotype in a small subset of anti-PD-1-treated metastatic melanoma patients [77] , although whether this simply represents a prognostic indicator or is predictive of worsening disease with anti-PD-1 therapy has not yet been demonstrated.
Tumor extrinsic mechanisms of resistance to ICB include the recruitment and activity of immune-suppressive cells, including MDSCs and Tregs [21, 22, 78, 79] . MDSCs are Microbiome dysbiosis [94, [97] [98] [99] [100] a heterogeneous group of immature myeloid cells (of both monocytic and granulocytic lineage) that are capable of promoting resistance to ICB by impairing the action of cytotoxic T lymphocytes via secretion of soluble factors [80] . Clinical correlative studies suggest that MDSCs are associated with clinical outcome in patients with melanoma [81, 82] . Circulating levels of MDSCs may also have prognostic significance [83] , however other circulating myeloid subsets have also been associated with response to PD-1 blockade [84] . Preclinical studies have demonstrated that selective targeting of myeloid cells (including MDSCs) enhanced response to ICB [85, 86] , and early-phase clinical testing is underway [87] . Tregs are a subset of immune-suppressive CD4 + T cells, initially defined by CD25 co-expression [88] and later defined by expression of the transcription factor FoxP3 [89, 90] . Tregs limit the effector function of cytotoxic CD8 + T cells through multiple mechanisms, including consumption of interleukin (IL)-2 (via CD25), secretion of immune-suppressive cytokines (e.g. IL-10, TGF-β), and upregulation of CTLA-4 [91] . Depletion of Tregs has been shown to enhance response to ICB in murine models, and is posited to underlie one of the potential mechanisms of action of CTLA-4 blockade in patients with melanoma via FcRmediated antibody-dependent cellular cytotoxicity [32, 33, 92] . Along with other immune-suppressive cell types (e.g. M2 tumor-associated macrophages), MDSCs and Tregs are candidates for combination therapies aimed at overcoming resistance to ICB. Additionally, efforts to reprogram tumorinfiltrating myeloid cells has shown promise in the preclinical setting [93] , suggesting that modulating macrophage phenotypes may be an additional strategy to enhance response (or overcome resistance) to ICB. Finally, alterations in the patient microbiome, primarily the gut flora, has been associated with both response and resistance to ICB [94] . While the specific mechanisms have not been well-established, the gut microbiota has been hypothesized to modulate the immune system through endocrine signaling of cytokines and IFNs, establishing a threshold for innate immunity activation [95] . In mouse models of ICB, germ-free or antibiotic-treated mice had attenuated anti-tumor effect of CTLA-4 and PD-1 blockade [96, 97] . In melanoma patients, decreased microbiome diversity has been associated with worse response to PD-1 checkpoint blockade [98, 99] , and the use of antibiotics in the peri-ICB setting was associated with worse PFS and OS [100] . In both mouse and human studies, specific species of bacteria have been found to be associated with 'good' and 'bad' responses to ICI, with effects transferrable (to mice) using fecal transplants, but there is little concordance between studies. Nonetheless, there is significant evidence for microbiome-induced immunomodulatory effects on ICI, and multiple trials are ongoing exploring the manipulation of the gut microbiome to enhance response to immunotherapy [94] .
Clinical Trials and Combinations
A large number of clinical trials are currently ongoing with novel immunotherapeutic agents, usually in combination with anti-CTLA4 or anti-PD1/PDL1 antibodies [101, 102] . We classify these trials into different types based on the targeted aspect of the tumor immunity cycle (Table 3) .
Various methods are being tested to generate the initial immune response with APC uptake and activation. Personalized vaccines (e.g. ClinicalTrials.gov [103, 104] ) are designed based on the individual patient's inferred tumor neoantigens. The vaccine, composed of a pool of the individualized tumor antigens, along with an adjuvant, is designed to induce the uptake and presentation of tumor-specific antigens by activated APCs, inducing the activation of neoantigen-specific T cells. In conjunction with PD-1/PD-L1 inhibition, this is designed to both generate a new immune response and induce a stronger response by blocking the inhibitory PD-1/PD-L1 signal. Another approach is the use of oncolytic viruses. Talimogene laherparepvec (T-VEC, Imlygic ® ), a herpes simplex virus genetically modified such that it can reproduce and spread using cancer cells, but not healthy cells, and encoding granulocyte-macrophage colony-stimulating factor to attract DCs and initiate an immune response [105] , has been demonstrated to induce response in unresectable melanoma lesions when injected intralesionally [106] , with the effect also extending to 15% of non-injected lesions. It has recently been shown that T-VEC in combination with ipilimumab in advanced (stage IIIB-IV) melanoma increased the overall RR (ORR), with an estimated odds ratio of 2.9 (p = 0.002), compared with ipilimumab alone [107] . Other oncolytic viruses such as the Coxsackie virus (e.g. CVA21), which are cytotoxic and target cell surface proteins (e.g. intercellular adhesion molecule-1 [ICAM-1] and decay-accelerating factor [DAF]) overexpressed in certain solid cancers [108] and in metastatic disease, are being tested in conjunction with immune checkpoint inhibitors [109] [110] [111] [112] in the hope of both inducing the initial phases of an immune response through tumor lysis, neoantigen exposure, and priming of APCs via virally-related DAMPs, activation of antigen-specific cytotoxic T cells (with anti-CTLA4 inhibitors), and strengthening of cytotoxic T-cell activity at the T-cell/tumor-cell interface with blockade of the PD-L1/PD-1 axis, while limiting clinical toxicity.
A second approach involves the direct generation of activated cytotoxic T cells with tumor specificity through adoptive cell therapy. This involves the collection of T cells from the patient, engineering to engraft a TCR that has specificity for a tumor antigen, expansion of this population, and reinfusion into the patient. This has been shown to be effective in hematologic malignancies where a target (e.g. CD19) on tumor cells (e.g. B-cell acute lymphoblastic leukemia [ALL]) has been identified, and all cells with that target can be destroyed with manageable toxicities (e.g. loss of all B cells, which can be managed with chronic infusions of immunoglobulin). Two chimeric antigen receptor T-cell (CAR-T) therapies have been FDA-approved (both targeting CD19) for pediatric B-cell ALL and types of diffuse large B-cell lymphoma [113] . However, such treatment results in significant toxicities, with a high proportion of cases experiencing cytokine release syndrome (CRS) caused by rapid, large release of immune-related cytokines into the blood, causing a severe sepsis-like phenotype, although CRS is associated with response. Furthermore, the recognition and management of CRS has significantly improved with IL-6 receptor blockers such as tocilizumab [114] . However, application in solid tumors (e.g. ClinicalTrials.gov [115] ) have had limited success, with major challenges, including identifying suitable targets and engineering TCRs with manageable toxicities/off-target effects. Recent failures included the cardiac failure and death of both patients treated with CAR-T cell therapy targeting the MAGE-A3 melanoma-specific antigen, with off-target detection of a similar peptide found in cardiac muscle [116] . Other issues include the time and expense needed to collect, engineer, expand, and reinfuse these engineered cells into patients. Nonetheless, advances in CAR-T cell design and trials are ongoing and represent the in vitro generation of an active immune response to tumors.
A third class of trials center around the combination of additional immune checkpoint targets with PD-1 or CTLA-4. For example, OX40/OX40L interaction is an important co-stimulatory signal for the generation of effector and memory T cells [117] . Trials are ongoing with delivery of intralesional OX40 messenger RNA (mRNA) encapsulated in a lipid nanoparticle (mRNA-2416) designed to release the mRNA into tumor and other cells in the tumor environment, and induce the expression of OX40, with the goal of enhancing the immune response at the tumor site [118] . Other examples include the development of ICOS-stimulatory antibodies (JTX-2011 [119] ) designed to increase cytotoxic T-cell function and reduce T-regulatory effect, and monoclonal antibodies blocking TIM-3, a negative checkpoint molecule found in exhausted T cells [120, 121] .
A fourth class of trials pairs ICB with targeted therapies or chemotherapies. For example, combination BRAF/MEKi and ICB is being tested in clinical trials [122] [123] [124] [125] . There is evidence that BRAF inhibition results in increased CD8 + T-cell infiltrate in patients with BRAF-mutant melanoma and increased melanoma antigen expression [126] . Whether this results from a direct effect on the immune response or increased tumor death from targeted therapy resulting in greater availability, uptake of tumor antigens, and activation of APCs, targeted therapies may cause tumor cell death and promotion of an immune response, which can then subsequently be amplified with ICB. Timing and sequencing of therapies is likely to be important to efficacy. In the frontline setting of metastatic NSCLC, the combination of chemotherapy and PD-1 blockade compared with standard-ofcare chemotherapy (with subsequent standard-of-care immunotherapy in the second-line setting) demonstrated improved overall survival [127] . In this setting, synergy may arise from immunogenic cell death, reduction of immunosuppressive immune cell subsets, or activation of cytotoxic immune cell populations [128] . A fifth class of trial targets other immunomodulatory cells or cytokines involved in the immune response. Inhibition of PI3K-γ has been demonstrated to switch the phenotype of macrophages from a immunosuppressive (M2) profile to an inflammatory (M1) profile with decreased cancer metastases and enhanced response to ICI in murine models [85, 87] , and is being tested in human clinical trials [129] . Other trials use agents that additionally target MDSCs [130, 131] or target immunosuppressive cytokines (e.g. anti-TGF-β [132] ). However, recent results demonstrating the failure of IDO (an immunosuppressive cytokine) inhibitors in conjunction with PD-1 inhibition [133] suggest that our understanding of the underlying biology and identification of promising targets is still incomplete, hindering our development of effective interventions.
Conclusions and Future Directions
Immune checkpoint inhibitors have revolutionized the management of melanoma and many solid tumor malignancies. While we have come a long way, we are truly just beginning to understand how these agents work and when they do not. Biologically, understanding the effect of ICI in different immune compartments, e.g. generation of memory, Tregs, and T helper cells, is needed to develop rational combination therapies. Clinically, our ability to predict whether an individual patient will respond or be resistant to ICI is poor outside of a small subset of patients. Most individual biomarkers have poor specificity and sensitivity, and the development of an integrated predictive model with features motivated by clear biological rationale that is rigorously tested will be necessary to inform clinical management and ideally help determine which patients may be effectively treated with single-agent therapy and which patients need potentially more toxic combinatorial regimens. However, it is only through an enhanced understanding of the tumor-immune interaction and its modulators (e.g. tumor type, tumor microenvironment, tumor site, tumor heterogeneity, and patient microbiome) and the mechanisms of clinical resistance to ICI that we will be able to design effective therapeutic combinations. Importantly, new technologies and tools (preclinical models, molecular characterization of clinical samples, development of new drugs and drug targets) have been and will continue to be developed that will be leveraged to assist the field to develop more effective treatments for our patients.
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